Genetically Engineered Antibody Molecules: New Tools for Cancer Therapy

References

• Kohler G, Milstrin C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (London) 1975; 256: 494–497
   Google Scholar
• Schlom J. Basic principles and applications of monoclonal antibodies in the management of carcinomas: The Richard and Hilda Rosenthal Foundation Award Lecture. Cancer Res 1986; 46: 3225–3238
   PubMed Web of Science ®Google Scholar
• Levy R L, Miller R A. Biological and clinical implications of lymphocyte hybridomas: Tumor therapy with monoclonal antibodies. Ann Rev Med 1983; 34: 107–127
   PubMed Web of Science ®Google Scholar
• Carrasquillo J A, Krohn K A, Beaumier P, et al. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 1984; 68: 317–325
   PubMedGoogle Scholar
• Houghton A N, Mintzer D, Cordon-Carda C, et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci (USA) 1985; 82: 1242–1246
   PubMed Web of Science ®Google Scholar
• Spira G, Bargellesi A, Teillaud J L, et al. The identification of monoclonal class switch variants by Sib selection and an ELISA assay. J Immunol Method 1984; 74: 307–315
   PubMed Web of Science ®Google Scholar
• Irie R, Morton D L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganghoside GD2. Proc Natl Acad Sci (USA) 1986; 83: 8694–8698
   PubMed Web of Science ®Google Scholar
• Teng N NH, Kaplan H, Hebert J M, et al. Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Nad Acad Sci (USA) 1985; 82: 1790–1794
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock H WL, Reiter C, Trenkmann J, et al. Protection of mice against tetanus toxin by combination of two human monoclonal antibodies recognizing distinct epitopes on the toxin molecule. Hybridoma 1986; 5: 21–31
   PubMed Web of Science ®Google Scholar
• Kenten J, Helm B, Ishizaka T, et al. Properties of a human immunoglobulin chain fragment synthesized in Escherichia coli. Proc Nad Acad Sci (USA) 1984; 81: 2955–2959
   PubMed Web of Science ®Google Scholar
• Kurokawa T, Seno M, Sasada R, et al. Expression of human immunoglobulin E e chain cDNA in E coli. Nucleic Acids Res 1983; 11: 3077–3085
   PubMed Web of Science ®Google Scholar
• Liu F-T, Albrandt K A, Bry C G, et al. Expression of a biologically active fragment of human IgE η chain in Escherichia coli. Proc Natl Acad Sci (USA) 1984; 81: 5369–5373
   PubMed Web of Science ®Google Scholar
• Boss M A, Kenten J H, Wood C R, et al. Assembly of functional antibodies from immunoglobulin heavy and light chains synthesized in E coli. Nucleic Acids Res 1984; 12: 3791–3806
   PubMed Web of Science ®Google Scholar
• Cabily S, Ribbs A D, Pande H. Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli. Proc Natl Acad Sci (USA) 1984; 81: 3273–3277
   PubMed Web of Science ®Google Scholar
• Klausner A. “Single-chain” antibodies become a reality. Bio/technology 1986; 4: 1041–1043
   Google Scholar
• Rice D, Baltimore D. Regulated expression of an immunoglobulin η gene introduced into a mouse lymphoid cell line. Proc Natl Acad Sci (USA) 1982; 79: 7862–7865
   PubMed Web of Science ®Google Scholar
• Oi V T, Morrison S L, Herzenberg L A, et al. Immunoglobulin gene expression in transformed lymphoid cells. Proc Nad Acad Sci (USA) 1983; 80: 825–829
   PubMed Web of Science ®Google Scholar
• Mulligan R C, Berg P. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyl-transferase. Proc Natl Acad Sci (USA) 1981; 78: 2072–2076
   PubMed Web of Science ®Google Scholar
• Southern P I, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1982; 1: 327–341
   PubMedGoogle Scholar
• Oi V T, Morrison S L. Chimeric antibodies. BioTechniques 1986; 4: 214–221
   Web of Science ®Google Scholar
• Davies J, Jimenez A. A new selective agent for eukaryotic cloning vectors. Am J Trop Med Hyg 1980; 29(5(Suppl.)1089–1092
   PubMed Web of Science ®Google Scholar
• Davies J, Smith D I. Plasmid-determined resistance to antimicrobial agents. Ann Rev Microbiol 1978; 32: 469–518
   PubMed Web of Science ®Google Scholar
• Franklin T J, Cook J M. The inhibition of nucleic acid synthesis by mycophendic acid. Biochem J 1969; 113: 515–524
   PubMed Web of Science ®Google Scholar
• Sandri-Goldin R M, Goldin A L, Levine M, et al. High-frequency transfer of cloned herpes simplex virus type 1 sequences to mammalian cells by protoplast fusion. Molec Cell Biol 1981; 1: 743–752
   PubMed Web of Science ®Google Scholar
• Potter H, Weir L, Leder P. Enhancer-dependent expression of human η immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Nad Acad Sci (USA) 1984; 81: 7161–7165
   PubMed Web of Science ®Google Scholar
• Storb U, Arp B, Wilson R. Myeloma with multiple rearranged immunoglobulin kappa genes: only one kappa gene codes for kappa chains. Nucleic Acids Res 1980; 8: 4681–4687
   PubMed Web of Science ®Google Scholar
• Sahagan B G, Dorai H, Saltzgaber-Muller J, et al. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. J Immunol 1986; 137: 1066–1074
   PubMed Web of Science ®Google Scholar
• Morrison S L, Wims L A, Wallick S, et al. Genetically engineered antibody molecules and their application. NY Acad Sci, (in press)
   Web of Science ®Google Scholar
• Liu A Y, Robinson R R, Hellstrom K E, et al. Chimeric mouse-human IgGl antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci (USA) 1987; 84: 3439–3443
   PubMed Web of Science ®Google Scholar
• Morrison S L, Johnson M J, Herzenberg L A, et al. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci (USA) 1984; 81: 6851–6855
   PubMed Web of Science ®Google Scholar
• Boulianne G L, Hozumi N, Shulman M J. Production of functional chimaeric mouse/human antibody. Nature (London) 1984; 312: 643–646
   PubMed Web of Science ®Google Scholar
• Neuberger M S, Williams G T, Mitchell E B, et al. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature (London) 1985; 314: 268–270
   PubMed Web of Science ®Google Scholar
• Brown B A, Davis G L, Saltzgaber-Muller J, et al. A tumor-specific genetically engineered murine/human chimeric MAb. Cancer Res, in press
   Google Scholar
• Sun L K, Curtis P, Rakowicz-Szulczynska E, et al. Chimeric antibodies with 17-lA-derived variable and human constant regions. Hybridoma 1986; 5(Suppl 1)S17–S20
   PubMedGoogle Scholar
• Sun L K, Curtis P, Rakowicz-Szulczynska E, et al. Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17–1A. Proc Natl Acad Sci (USA) 1987; 84: 214–218
   PubMed Web of Science ®Google Scholar
• Neuberger M S, Williams G T, Fox R O. Recombinant antibodies possessing novel effector functions. Nature (London) 1984; 312: 604–608
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Baudhrihaye M F, Chkoff N, et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986; 137: 830–838
   PubMed Web of Science ®Google Scholar
• Shawler D L, Bartholomew R M, Smith L A, et al. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530–1535
   PubMed Web of Science ®Google Scholar
• Herlyn D, Sears H, Ililopoulos D, et al. Anti-idiotypic antibodies to monoclonal antibody C017-1A. Hybridoma 1986; 5(Suppi 1)S51–S58
   PubMedGoogle Scholar
• Herlyn D, Lubeck M, Sears H, et al. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J Immunol Methods 1985; 74: 27–38
   Google Scholar
• Benjamin R J, Cobbold S P, Clark M R, et al. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med 1986; 163: 1539–1552
   PubMed Web of Science ®Google Scholar
• Verrill H, Goldberg M, Rosenbaum R, et al. Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: a preliminary report. Hybridoma 1986; 5(Suppl 1)S175–S183
   PubMedGoogle Scholar
• Jones P T, Dear P H, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (London) 1986; 321: 522–525
   PubMed Web of Science ®Google Scholar